Bayer Stock Tests Key Level as Trade Probe, Glyphosate Settlement and Supreme Court Ruling Converge
22.06.2026 - 02:44:34 | boerse-global.de
The Leverkusen-based pharmaceutical and agricultural giant enters a multi-front week with its share price perched just above a critical technical marker. The stock closed Friday at €37.81, a whisker above its 50-day moving average of €37.80 — a zone chart-watchers consider a short-term buy signal. The relative strength index sits at 55.8, indicating room to run before becoming overbought.
Yet the technical setup is only part of the story. A thicket of legal, regulatory and commercial catalysts is closing in, each capable of swinging the equity sharply in either direction.
Washington has opened a fresh front. The US Trade Representative, Jamieson Greer, launched a Section 301 investigation into Germany’s drug-pricing policies, alleging they disadvantage American patients and manufacturers. The probe follows months of apparently fruitless talks with Berlin. Its immediate trigger: a German government plan to close a roughly €20 billion hole in the statutory health insurance system through a savings package, the parliamentary vote on which has been pushed back to July. A hearing is scheduled for September, with public comments due in August. Should the US ultimately impose tariffs on German medicines, Bayer — which operates key R&D and production sites in Germany — would have to recalculate margins in its critical North American business.
Should investors sell immediately? Or is it worth buying Bayer?
Against this political risk, the glyphosate litigation that has plagued the company for years is edging closer to resolution. On June 17, US federal judge Henry Edward Autrey sent the multibillion-dollar class-action settlement back to a Missouri state court, blocking plaintiffs’ attorneys from moving the case to a more hostile venue in California. The settlement, valued at $7.25 billion, received preliminary approval from state judge Timothy Boyer in March. A final fairness hearing is scheduled for July 9, 2026. If it passes without complications, Bayer could close this long-running overhang by year-end — though a separate Supreme Court ruling expected at the end of June will set the tone for the broader legal environment.
Meanwhile, Bayer is pressing ahead with pipeline moves and competitive defenses. On June 17 it completed the acquisition of Perfuse Therapeutics, gaining full rights to PER-001, an intravitreal implant with sustained-release technology now in Phase II trials for glaucoma and diabetic retinopathy. The upfront payment was $300 million, with the total deal value potentially reaching $2.45 billion depending on milestones. The purchase bolsters the company’s ophthalmology pipeline.
In parallel, Bayer escalated a legal dispute with Johnson & Johnson over the prostate cancer drug Erleada. On June 15 it filed an amended complaint, accusing J&J of using a flawed real-world analysis to claim Erleada’s superiority over Bayer’s own Nubeqa. Bayer is seeking a permanent injunction and damages.
Analysts remain split. UBS reiterated a “buy” with a price target of €52, arguing the stock is undervalued. Jefferies sticks with “hold” and a target of €40, pointing to the lingering uncertainty from the Supreme Court case. For the seven-day stretch to Friday, the stock gained nearly 5 percent, recovering more than 50 percent from its 52-week low of €25.09 — yet on a 12-month view it stands virtually flat. The 100-day moving average at €39.69 offers the next upside target, but the path to it runs through a gauntlet of court dates and trade talks that could just as easily push the equity back down.
Ad
Bayer Stock: New Analysis - 22 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
